Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Adrenocorticotropic Hormone, Calcitonin, Insulin), Route of Administration, Application, End User, Manufacturing Type - Global Forecast 2024-2030
Description
Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Adrenocorticotropic Hormone, Calcitonin, Insulin), Route of Administration, Application, End User, Manufacturing Type - Global Forecast 2024-2030
The Peptide Therapeutics Market size was estimated at USD 33.06 billion in 2023 and expected to reach USD 35.76 billion in 2024, at a CAGR 8.35% to reach USD 57.97 billion by 2030.
Peptide therapeutics use short chains of amino acids to treat or control various diseases and medical conditions. These biologically active molecules possess unique properties, making them an efficient drug development and pharmaceutical research option. The surging prevalence of chronic diseases, including cancer and diabetes, is raising the need for effective treatment options and an improved understanding of protein-protein interactions leading to targeted therapies. The growing investment in research & development activities and a robust clinical pipeline with therapeutic candidates result in novel peptide therapeutics being developed. However, the inherent instability of peptides and the high cost of manufacturing peptides may adversely impact the development of peptide therapeutics. Moreover, recent developments in drug delivery systems and the development of new peptides are expected to expand the potential applications for peptides.
Regional Insights
The peptide therapeutics market is evolving in the Americas due to well-established pharmaceutical industries, increased research activities, and a growing number of approved peptide drugs. Patent activity in this region is notable, with several major pharmaceutical companies headquartered in the area. In recent years, investments in innovative peptide formulations have increased, indicating a robust market potential for new therapeutic approaches. The rising prevalence of chronic disease, improving healthcare infrastructure, and growing awareness regarding peptide therapeutics are encouraging the growth of the peptide therapeutics market in the APAC region. In addition, ongoing advancements and the development of efficient, scalable, and cost-effective synthetic strategies for producing peptides are anticipated to encourage the adoption of peptide therapeutics globally. The peptide therapeutics market is developing in the EMEA region owing to the regulatory framework supporting innovation within biotechnology and funding research projects related to peptide therapeutics. The European Union demonstrates a well-established market for peptide therapeutics, supported by comprehensive healthcare systems and a high degree of awareness regarding advanced treatment options. The EU's regulatory framework, through the European Medicines Agency (EMA), has been instrumental in approving and monitoring peptide-based drugs. The peptide therapeutics market in the African region is currently growing steadily, characterized by growing research activities and increasing awareness toward advanced therapeutic options.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Peptide Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Prevalence of chronic diseases and need for effective therapeutic options
- Exponential use of peptides in aesthetic dermatology
- Market Restraints
- Adverse recalls of peptide therapeutics
- Market Opportunities
- Ongoing R&D activities for new peptide development worldwide
- Shift toward personalized medicine and identification of peptide biomarkers
- Market Challenges
- Production complexity and bioavailability issues of peptide therapeutics
- Market Segmentation Analysis
- Technology: Rising utilization of solid phase approach for synthesis of complex peptides
- Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes
- Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings
- Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation
- End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions
- Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Peptide Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Peptide Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Expansion of GMP Capacities at CordenPharma Frankfurt: Elevating Early-Phase Peptide API Manufacturing
CordenPharma introduced new GMP capacities at its Frankfurt site, marking a significant step in its ongoing efforts to support early clinical phase drug development. Slated for full operational readiness in Q2 2024 with authorization from German authorities expected in H2 2024, this expansion adds 1000 m² of manufacturing space featuring cutting-edge Solid Phase Peptide Synthesis (SPPS) and High-Pressure Liquid Chromatography (HPLC), among other technologies. This initiative highlights CordenPharma’s commitment to integrated service offerings, linking Peptide Drug Substance production in Frankfurt with Injectable Drug Products in Caponago (Italy), thus facilitating efficient Investigational New Drug (IND) / Investigational Medicinal Product Dossier (IMPD) submissions and the initiation of First In-Human (FIH) clinical trials.
Revolutionizing Peptide Therapeutics: Orbis Medicines Innovates for Oral Drug Delivery
Orbis Medicines emerged from stealth mode, indicating an advanced step in the field of peptide therapeutics with a substantial EUR 26 million seed funding led by Novo Holdings and Forbion. The company is at the forefront of developing peptide-based drugs that can be administered orally, offering a promising alternative to the conventional, and often burdensome, injectable biologics used for chronic conditions. The platform employs highly automated chemical synthesis and screening processes, accelerated by machine learning techniques, to rapidly produce potential drug candidates optimized for oral administration.
Expanding Facilities in Peptide Therapeutic Production: WuXi AppTec's Strategic Growth
WuXi AppTec advanced its manufacturing capabilities with the opening of two new peptide manufacturing facilities, located at Changzhou and the newly established Taixing site in Jiangsu, China. This expansion significantly enhanced the company’s Solid-Phase Peptide Synthesis (SPPS) capabilities, increasing its total reactor volume to 32,000 liters. Leveraging state-of-the-art digital operation systems, these facilities are equipped with automated solvent delivery mechanisms designed to optimize production consistency, reduce cycle times, and minimize human error.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Peptide Therapeutics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Peptide Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AmbioPharm, Inc., Amgen Inc., Amide Technologies, Inc., AstraZeneca PLC, Bachem Holding AG, Biosynth Ltd., Bristol Myers Squibb Company, Cidara Therapeutics, Inc., Corden Pharma International GmbH, Cybrexa, Inc., Eccogene, Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ipsen Group, IRBM S.p.A., Ironwood Pharmaceuticals, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Peptidream Co., Ltd., Perpetual Medicines Corporation, Pfizer Inc., Piramal Pharma Limited, PolyPeptide Group AG, RELIEF THERAPEUTICS Holding SA, Sanofi S.A., Sanyou Biopharmaceuticals Co., Ltd., Shanghai Full-Life Technologies Co, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, WuXi AppTec Co., Ltd., and Zealand Pharma A/S.
Market Segmentation & Coverage
This research report categorizes the Peptide Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:- Technology
- Hybrid Phase
- Liquid Phase
- Solid Phase
- Drug Class
- Adrenocorticotropic Hormone
- Calcitonin
- Insulin
- Leuprorelin
- Octreotide
- Vasopressin
- Route of Administration
- Intravenous Administration
- Nasal & Pulmonary Administration
- Oral Administration
- Transdermal Administration
- Application
- Cardiovascular Disorders
- Gastrointestinal Disorders
- Infectious Disorders
- Neurological Disorders
- Oncology
- End User
- Hospitals & Clinics
- Long-term Care Facilities
- Research Laboratories
- Manufacturing Type
- Contract Manufacturing Organization
- In-house
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- Indiana
- Maryland
- Massachusetts
- Minnesota
- New Jersey
- New York
- North Carolina
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Market Drivers
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Prevalence of chronic diseases and need for effective therapeutic options
- 5.1.1.2. Exponential use of peptides in aesthetic dermatology
- 5.1.2. Restraints
- 5.1.2.1. Adverse recalls of peptide therapeutics
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing R&D activities for new peptide development worldwide
- 5.1.3.2. Shift toward personalized medicine and identification of peptide biomarkers
- 5.1.4. Challenges
- 5.1.4.1. Production complexity and bioavailability issues of peptide therapeutics
- 5.2. Market Segmentation Analysis
- 5.2.1. Technology: Rising utilization of solid phase approach for synthesis of complex peptides
- 5.2.2. Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes
- 5.2.3. Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings
- 5.2.4. Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation
- 5.2.5. End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions
- 5.2.6. Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly
- 5.3. Market Trend Analysis
- 5.3.1. Expanding pharmaceutical R&D activities and growing government investment to strengthen the healthcare sector in the Americas
- 5.3.2. Significant public and private investment in advanced research facilities and technologies in the Asia-Pacific region
- 5.3.3. Enhancement in peptide manufacturing capabilities, exploring new application areas, and presence of major players in the EMEA region
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework Analysis
- 6. Peptide Therapeutics Market, by Technology
- 6.1. Introduction
- 6.2. Hybrid Phase
- 6.3. Liquid Phase
- 6.4. Solid Phase
- 7. Peptide Therapeutics Market, by Drug Class
- 7.1. Introduction
- 7.2. Adrenocorticotropic Hormone
- 7.3. Calcitonin
- 7.4. Insulin
- 7.5. Leuprorelin
- 7.6. Octreotide
- 7.7. Vasopressin
- 8. Peptide Therapeutics Market, by Route of Administration
- 8.1. Introduction
- 8.2. Intravenous Administration
- 8.3. Nasal & Pulmonary Administration
- 8.4. Oral Administration
- 8.5. Transdermal Administration
- 9. Peptide Therapeutics Market, by Application
- 9.1. Introduction
- 9.2. Cardiovascular Disorders
- 9.3. Gastrointestinal Disorders
- 9.4. Infectious Disorders
- 9.5. Neurological Disorders
- 9.6. Oncology
- 10. Peptide Therapeutics Market, by End User
- 10.1. Introduction
- 10.2. Hospitals & Clinics
- 10.3. Long-term Care Facilities
- 10.4. Research Laboratories
- 11. Peptide Therapeutics Market, by Manufacturing Type
- 11.1. Introduction
- 11.2. Contract Manufacturing Organization
- 11.3. In-house
- 12. Americas Peptide Therapeutics Market
- 12.1. Introduction
- 12.2. Argentina
- 12.3. Brazil
- 12.4. Canada
- 12.5. Mexico
- 12.6. United States
- 13. Asia-Pacific Peptide Therapeutics Market
- 13.1. Introduction
- 13.2. Australia
- 13.3. China
- 13.4. India
- 13.5. Indonesia
- 13.6. Japan
- 13.7. Malaysia
- 13.8. Philippines
- 13.9. Singapore
- 13.10. South Korea
- 13.11. Taiwan
- 13.12. Thailand
- 13.13. Vietnam
- 14. Europe, Middle East & Africa Peptide Therapeutics Market
- 14.1. Introduction
- 14.2. Denmark
- 14.3. Egypt
- 14.4. Finland
- 14.5. France
- 14.6. Germany
- 14.7. Israel
- 14.8. Italy
- 14.9. Netherlands
- 14.10. Nigeria
- 14.11. Norway
- 14.12. Poland
- 14.13. Qatar
- 14.14. Russia
- 14.15. Saudi Arabia
- 14.16. South Africa
- 14.17. Spain
- 14.18. Sweden
- 14.19. Switzerland
- 14.20. Turkey
- 14.21. United Arab Emirates
- 14.22. United Kingdom
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2023
- 15.2. FPNV Positioning Matrix, 2023
- 15.3. Competitive Scenario Analysis
- 15.3.1. Expansion of GMP Capacities at CordenPharma Frankfurt: Elevating Early-Phase Peptide API Manufacturing
- 15.3.2. Revolutionizing Peptide Therapeutics: Orbis Medicines Innovates for Oral Drug Delivery
- 15.3.3. Expanding Facilities in Peptide Therapeutic Production: WuXi AppTec's Strategic Growth
- 15.3.4. Glenmark Pharmaceuticals Announces Biosimilar Liraglutide Launch in India to Revolutionize Anti-Diabetic Treatment
- 15.3.5. Amide Technologies' Novel Manufacturing Platform and Strategic Capital Advancement
- 15.3.6. Strategic Acquisition Elevates Pharmathen's Position in the Peptide Therapeutics Market
- 15.3.7. Biosynth Solidifies Market Position with Strategic Acquisition of Pepceuticals
- 15.3.8. Strategic Collaboration between PeptiDream and Genentech to Advance Peptide-Radioisotope Therapeutics
- 15.3.9. Merck and IRBM Forge Forward in Peptide Therapeutics: A Partnership to Expand and Innovate in Biopharmaceuticals
- 15.3.10. Fujitsu Launches Pioneering Bio-Drug Design Accelerator Focused on Advancing Peptide Therapeutics in Cancer and CNS Regeneration
- 15.3.11. Comprehensive Support for Peptide Therapeutics Development from Conception to Manufacturing for Introducing SynCrest's CRDMO Service
- 16. Competitive Portfolio
- 16.1. Key Company Profiles
- 16.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
